bioMérieux : CA T2 2020 toujours dynamique et en ligne avec notre attente - Prévisions FY ajustées (+5%e) – OC : 117 € vs 113 € – Neutre vs Achat
>Pré-annonce du CA T2 : assez conforme - Le CA T2 se monte à 707 M€e. Comme au T1, la croissance est clairement tirée par la Biologie Moléculaire (+62% vs +70%e) qui représente désormais 37% du CA (vs plutôt 25% en 2019).A fin juin, la croissance ressort à 15,8% et 15.7% à tcc, soit 1 476 M€e (vs 1 466 M€e).Le détail du chiffre d’affaires du 2ième trimestre ainsi que les résultats financiers du premier semestre seront publiés le 2 septembre 2020. Enfin,...Co. specializes in the field of in vitro diagnostics for clinical and industrial applications. Co. designs, develops, manufactures and markets systems used in: Clinical Applications (the diagnosis of infectious diseases such as hepatitis, HIV, tuberculosis and respiratory illnesses, as well as pathologies such as cardiovascular diseases and cancers, based on the analysis of biological samples such as blood, saliva or urine); and Industrial Applications (microbiological analysis of samples of finished or semi-finished products (or of the environment), chiefly in the food processing and biopharmaceutical industries), detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.